

ELLEX MEDICAL LASERS LIMITED (ELX) ASX RELEASE

FOR IMMEDIATE RELEASE

5 November 2004

Ellex Launches New Photocoagulator

Ellex Medical Lasers Limited (Ellex) has launched the first product in its new range of photocoagulators targeting the large retinal ophthalmic laser segment, at the American Academy of Ophthalmology ("AAO"), in New Orleans.

The retinal ophthalmic laser market is estimated to be worth approximately US\$150 million and Ellex believes that the new product will grow its current share of this market – currently at around 4%.

The "Solitaire™" is a new 532nm laser suitable for a wide range of applications in the office clinic, as well as the operating room. The product is the first of a series of lasers that Ellex expects to release over the next two years to expand into this segment and was developed with the support of an R&D Start Grant from the Australian Government business unit, AusIndustry. The R&D Start Grant is a competitive scheme directed at encouraging innovative research in Australia.

The key features of the product are its dual port capability that allows for two delivery devices to be attached at any time, and automatic device recognition. This is the only photocoagulator on the market with these features, saving the doctor considerable set up time and offering greater convenience.

Managing Director, Victor Previn, said that both distributors and doctors were very positive about the new product at the AAO, and applauded its excellent features.

"We expect to move into pilot production phase late this calendar year and into full production by mid June 2005. Product sales are expected to ramp up over the next twelve (12) months and, based on the AAO feedback, we are confident this product will prove to be a successful addition to our range".

ABOUT ELLEX

Ellex Medical Lasers Limited leads the world in the supply of innovative integrated laser systems for use by eye surgeons throughout the world under its brand "Laserex". Ellex has been manufacturing lasers for more than 15 years and our extensive range includes Nd:YAG Laser Photodisruptors and Green Laser Photocoagulators for retinal treatment. Ellex is currently pioneering the development of Selective Laser Trabeculoplasty (SLT) as a treatment for elevated IOP in patients with Glaucoma and is the only manufacturer of the SLT/YAG combination Laser.

For more information about the company log on to our web site at www.ellex.com.au

FOR FURTHER INFORMATION, please contact:

Victor Previn, Managing Director - Ellex Medical Lasers Limited – 08 8104 5200/0414 661 994
David Lindh, Chairman – Ellex Medical Lasers Limited – 08 8233 5555/0411 862 695